Lonsurf in clinical practice – case report
05/2017
MUDr. Beatrix Bencsiková, Ph.D.
Masarykův onkologický ústav, Brno
SUMMARY
Trifluridin/tipiracil (Lonsurf, TAS-102) represents a new option for the treatment of patients with metastatic colorectal cancer (mCRC) on the 3rd and upper line. It reduces the risk of death by 31% compared to placebo (overall survival, OS 71 vs. 5.3 months, hazard ratio [HR], 95% CI 0.68 [0.58-0.81], p < 0.001), and a risk of disease progression by 52% compared to placebo (progression free survival [PFS] 2.0 vs. 1.7 months, p < 0.001), confirmed by the phase III clinical trial RECOURSE [1]. The benefit was observed in all subgroups of patients regardless of the KRAS mutation, refractoriness to 5-fluorouracil in previous lines. The following case study confirms the benefit of the combination of trifluridine/tipiracil in a pre-treated patient with mCRC.
KEY WORDS
TAS-102, metastatic colorectal cancer, chemotherapy
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...